Editorial overview: cancer: from target discovery to targeted therapy: the risky business of target validation.

Curr Opin Pharmacol

Translational Science, Oncology iMED, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK. Electronic address:

Published: August 2014

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coph.2014.08.004DOI Listing

Publication Analysis

Top Keywords

editorial overview
4
overview cancer
4
cancer target
4
target discovery
4
discovery targeted
4
targeted therapy
4
therapy risky
4
risky business
4
business target
4
target validation
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!